5 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 5 Phase 1, 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 5 | Completed 2, Terminated 2, Active not recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow PureTech: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) Deupirfenidone, Pirfenidone (PFD) - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Recruiting | PureTech | 1100 | 2026-06-26 | 2026-10-23 |
| Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib Nintedanib 150 MG [Ofev] - Drug Interactions | Phase 1 | Completed | PureTech | 24 | 2024-12-17 | 2026-08-13 |
| A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) LYT-200, Venetoclax, Azacitidine - AML, Adult Recurrent, MDS | Phase 1 | Completed | PureTech | 101 | 2022-12-12 | 2026-05-06 |
| LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Placebo, Pirfenidone, Deupirfenidone - Idiopathic Pulmonary Fibrosis | Phase 2 | Active not recruiting | PureTech | 240 | 2022-07-22 | 2025-10-16 |
| LYT-300 in Healthy Volunteers LYT-300, Placebo - Healthy Volunteers | Phase 1 / Phase 2 | Completed | PureTech | 186 | 2021-12-07 | 2023-11-13 |
| PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects Deupirfenidone, Pirfenidone (PFD), Placebo - Pharmacokinetic Analysis | Phase 1 | Completed | PureTech | 116 | 2021-07-12 | 2026-03-06 |
| LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel - Metastatic Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | PureTech | 44 | 2020-12-15 | 2025-02-12 |
| LYT-100 in Post-acute COVID-19 Respiratory Disease LYT-100, Placebo - Covid19, Post-acute COVID-19 Respiratory Disease | Phase 2 | Terminated | PureTech | 185 | 2020-12-11 | 2026-06-23 |
| LYT-100 in Patients With BCRL LYT-100 BCRL, Placebo BCRL - Breast Cancer Related Lymphoedema, Lymphoedema | Phase 2 | Terminated | PureTech | 50 | 2020-03-01 | 2024-04-23 |
Pulmonary Fibrosis (4) · Idiopathic Pulmonary Fibrosis (3) · Bile Duct Neoplasms (1) · COVID-19 (1) · Carcinoma, Transitional Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Lymphedema (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Post-Acute COVID-19 Syndrome (1)
pirfenidone (6) · Azacitidine (1) · Decitabine (1) · nintedanib (1) · tislelizumab (1) · venetoclax (1)
United States (7) · Australia (3) · Argentina (2) · Philippines (2) · Romania (2) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Georgia (1) · Greece (1) · India (1) · Malaysia (1) · Mexico (1) · Moldova (1)
Aleksandra Filipovic, MD, Ph.D. (1) · Aleksandra Filipovic, MD, PhD. (1) · Bruce G Rankin, DO (1) · Camilla Graham, MD (1) · Michael A Hassman, DO (1) · Steven H Reynolds, DO (1) · Toby Maher, MD (1)
PMID 34779583, PMID 40692836, PMID 42085224
2025 (1)